English Polski

Wyszuk. zaawans.

Tom 3, Nr 1 (2010)
SPRAWOZDANIA, KOMUNIKATY
Opublikowany online: 2010-03-19

dostęp otwarty

Pokaż PDF Pobierz plik PDF
Wyświetlenia strony 365
Wyświetlenia/pobrania artykułu 1332
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Raport z 7th Inhibitor Workshop for Opinion Leaders in Haemophilia, Antalya, Turcja, 24-26 czerwca 2009 roku

Redakcja JTM
Journal of Transfusion Medicine 2010;3(1):35-46.

Streszczenie

Brak

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Shattil SJ, Bennett JS. Platelets and their membranes in hemostasis: physiology and pathophysiology. Ann Intern Med. 1981; 94(1): 108–118.
    PubMed
  2. Krudysz-Amblo J, Parhami-Seren B, Butenas S, et al. Quantitation of anti-factor VIII antibodies in human plasma. Blood. 2009; 113(11): 2587–2594.
    CrossRefPubMed
  3. Brackmann HH, Effenberger E, Hess L, et al. NovoSeven in immune tolerance therapy. Blood Coagul Fibrinolysis. 2000; 11 Suppl 1: S39–S44.
    PubMed
  4. Rodriguez-Merchan EC. Haemophilic synovitis: basic concepts. Haemophilia. 2007; 13 Suppl 3: 1–3.
    CrossRefPubMed
  5. Gomperts ED, Astermark J, Gringeri A, et al. From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia a patients with inhibitors. Blood Rev. 2008; 22 Suppl 1: S1–11.
    CrossRefPubMed
  6. Brackmann HH, Effenberger W, Hess L, et al. Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)? Eur J Haematol Suppl. 1998; 63: 18–23.
    PubMed
  7. Rodriguez-Merchan EC, Quintana M, Jimenez-Yuste V, et al. Orthopaedic surgery for inhibitor patients: a series of 27 procedures (25 patients). Haemophilia. 2007; 13(5): 613–619.
    CrossRefPubMed
  8. Hillarp A, Berntorp E. Non-inhibitory antibodies in the MIBS cohort. J Thromb Haemostas. 2009; 7(supl. 2): abstract.
  9. Windyga J, Chojnowski K, Klukowska A, et al. Zasady postępowania w hemofilii A i B. Acta Haematol Pol. 2008; 39: 537–564.
  10. Brackmann HH, Lenk H, Scharrer I, et al. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia. 1999; 5(3): 203–206.
    PubMed
  11. Santagostino E, Morfini M, Auerswald GKH, et al. Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs. Haemophilia. 2009; 15(5): 983–989.
    CrossRefPubMed
  12. Enjeti AK, Lincz LF, Seldon M. Microparticles in health and disease. Semin Thromb Hemost. 2008; 34(7): 683–691.
    CrossRefPubMed
  13. Ahnström J, Berntorp E, Lindvall K, et al. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia. 2004; 10(6): 689–697.
    CrossRefPubMed
  14. Tjønnfjord GE, Tjønnfjord GE, Brinch L, et al. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia. 2004; 10(2): 174–178.
    PubMed
  15. Bakewell SJ, Nestor P, Prasad S, et al. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A. 2003; 100(24): 14205–14210.
    CrossRefPubMed
  16. Daldrup-Link HE, Steinbach L. MR imaging of pediatric arthritis. Magn Reson Imaging Clin N Am. 2009; 17(3): 451–467.
    CrossRefPubMed
  17. DiMichele DM, Hoots WK, Pipe SW, et al. International workshop on immune tolerance induction: consensus recommendations. Haemophilia. 2007; 13 Suppl 1: 1–22.
    CrossRefPubMed
  18. Brill A, Elinav H, Varon D. Differential role of platelet granular mediators in angiogenesis. Cardiovasc Res. 2004; 63(2): 226–235.
    CrossRefPubMed
  19. Doria AS, Lundin B, Kilcoyne RF, et al. Reliability of progressive and additive MRI scoring systems for evaluation of haemophilic arthropathy in children: expert MRI Working Group of the International Prophylaxis Study Group. Haemophilia. 2005; 11(3): 245–253.
    CrossRefPubMed
  20. DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol. 2007; 138(3): 305–315.
    CrossRefPubMed
  21. Lauroua P. Ferrer A.M., Guerin V. Successful major and minor surgery using factor VIII inhibitor bypassing activity in patients with haemophilia A and inhibitors. Haemophilia. 2009; 29: 1–8.
  22. Kraut EH, Aledort LM, Arkin S, et al. Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review. Haemophilia. 2007; 13(5): 508–517.
    CrossRefPubMed
  23. Di Paola J, Aledort L, Britton H, et al. Application of current knowledge to the management of bleeding events during immune tolerance induction. Haemophilia. 2006; 12(6): 591–597.
    CrossRefPubMed
  24. Calvete JJ. Clues for understanding the structure and function of a prototypic human integrin: the platelet glycoprotein IIb/IIIa complex. Thromb Haemost. 1994; 72(1): 1–15.
    PubMed
  25. Gringeri AA. 10-year, randomized clinical trial on prophylaxis vs. on demand treatment in children with haemophilia A: the E. S P R I T study. Haemophilia. 2008; 14(supl. 2): 99.
  26. White JG, Krumwiede MD, Cocking-Johnson D, et al. Induction of GPIb/IX-vWF Receptor-Ligand Translocation on Surface-Activated Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology. 1995; 15(5): 642–654.
    CrossRef
  27. Jiménez-Yuste V, Rodriguez-Merchan E, Alvarez M, et al. Controversies and Challenges in Elective Orthopedic Surgery in Patients With Hemophilia and Inhibitors. Seminars in Hematology. 2008; 45: S64–S67.
    CrossRef
  28. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007; 357(6): 535–544.
    CrossRefPubMed
  29. Zwall RFA. Membrane and lipid involvement In blond coagulation. 1978; 515: 163–205.
  30. Hay CRM. The epidemiology of factor VIII inhibitors. Haemophilia. 2006; 12 Suppl 6: 23–28.
    CrossRefPubMed
  31. Hilgartner MW, Makipernaa A, Dimichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia. 2003; 9(3): 261–268.
    PubMed
  32. Enjeti AK, Lincz LF, Seldon M. Microparticles in health and disease. Semin Thromb Hemost. 2008; 34(7): 683–692.
    CrossRefPubMed
  33. Coppola A, Franchini M, Tagliaferri A, et al. Prophylaxis in people with haemophilia. Thromb Haemost. 2009; 101: 674–681.
  34. Habermann B, Hochmuth K, Hovy L, et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis. 1996; 26 Suppl 1(6): 118–123.
    PubMed
  35. Hermans C. Clinical relevance of subclinical bleeds. Abstract book 7 th inhibitor workshoop for opinion leaders in haemophilia. , Antalya Turkey 2009: 11.
  36. Kreuz W, Escuriola-Ettinghausen C, Mentzer D, et al. Factor VIII inhibitor bypass activity (FEIBA) for prophylaxis during immune tolerance induction (ITI) in patients with high-responding inhibitors. Blood. 2000; 96(11): 266a.
  37. Kruse-Jarres R, Barnett B, Leissinger C. Immune tolerance induction for the eradication of inhibitors in patients with hemophilia A. Expert Opin Biol Ther. 2008; 8(12): 1885–1896.
    CrossRefPubMed
  38. Leissinger CA, Becton DL, Ewing NP, et al. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia. 2007; 13(3): 249–255.
    CrossRefPubMed
  39. Lusher J, Ingerslev J, Roberts H, et al. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis. 1998; 9(2): 119–128.
    PubMed
  40. Manno CS. Treatment options for bleeding episodes in patients undergoing immune tolerance therapy. Haemophilia. 1999; 5 Suppl 3: 33–41.
    PubMed
  41. Odeyemi IAO, Danø AM. Optimising immune tolerance induction strategies in the management of haemophilia patients with inhibitors: a cost-minimisation analysis. Curr Med Res Opin. 2009; 25(1): 239–250.
    CrossRefPubMed
  42. Oldenburg J, Schwaab R, Brackmann HH. Induction of Immune Tolerance in Haemophilia A Inhibitor Patients by the ‘Bonn Protocol’: Predictive Parameter for Therapy Duration and Outcome. Vox Sanguinis. 1999; 77(Suppl. 1): 49–54.
    CrossRef
  43. Petrini P, Klementz G. Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy. Blood Coagul Fibrinolysis. 1998; 9 Suppl 1: S143–S146.
    PubMed
  44. Saxon BR, Shanks D, Jory CB, et al. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint. Thromb Haemost. 2001; 86(4): 1126–1127.
    PubMed
  45. Schapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomized trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemostas. 1998; 80: 773–778.
  46. Schneiderman J, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia. 2004; 10(4): 347–351.
    CrossRefPubMed
  47. Tjønnfjord GE. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience. Haemophilia. 2004; 10 Suppl 2: 41–45.
    CrossRefPubMed
  48. Valentino L.A. FEIBA prophylaxis in hemophilia A patients with inhibitors results in a 95% reduction in bleeding episodes. Bangkok, Thailand: Poster presented at 26 th World Federation of Haematology Congress October Bangkok, 2004.
  49. VALENTINO LA. FEIBA prophylaxis for patients with haemophilia and inhibitors. Haemophilia. 2006; 12(s5): 26–31.
    CrossRef
  50. Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia. 2003; 9(4): 436–463.
    PubMed
  51. Windyga J, Chojnowski K, Klukowska A, et al. Zasady postępowania w hemofilii A i B powikłanej inhibitorem. Acta Haematologica Polonica. 2008; 38(3): 565–579.

Informacje o plikach cookie

Niezbędne pliki cookie

Zawsze aktywne

Te pliki cookie są niezbędne do prawidłowego wyświetlania i działania strony internetowej. Zablokowanie ich może spowodować nieprawidłowe działanie strony.

Analityczne pliki cookie

W ramach naszej strony internetowej korzystamy z narzędzi analitycznych, takich jak Google Analytics, które umożliwiają nam weryfikację ruchu na stronie internetowej. Narzędzia te mogą wymagać użycia plików cookie.

Społecznościowe pliki cookie

Są to pliki cookie powiązane z portalami społecznościowymi, z których korzystamy. Zaakceptowanie ich pozwoli na powiązanie Twojej wizyty na stronie z naszymi profilami w mediach społecznościowych.

Marketingowe pliki cookie

Są to pliki cookie odpowiedzialne za prowadzenie działań reklamowych i marketingowych - zgoda na ich wykorzystanie pozwoli nam kierować do Ciebie reklamy, bazujące na podstawie Twoich wcześniejszych aktywności w ramach naszej stronie internetowej.

Journal of Transfusion Medicine

O Via Medica Reklama
Księgarnia (Ikamed) TVMed
Aktualności
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice